Tessera Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
348
- Latest Deal Type
-
Later Stage VC
- (In Progress)
- Investors
-
24
Tessera Therapeutics General Information
Description
Developer of gene writing technology designed to make permanent small and large alterations to the human genome. The company's technology helps scientists and clinicians with the ability to write small and large therapeutic messages into the genome to treat diseases at their source, thereby enabling healthcare providers to cure their patients and improve their lives.
Contact Information
Website
www.tesseratherapeutics.comCorporate Office
- 55 Cambridge Parkway
- Suite 800 East
- Cambridge, MA 02142
- United States
Corporate Office
- 55 Cambridge Parkway
- Suite 800 East
- Cambridge, MA 02142
- United States
Tessera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 18-Dec-2024 | In Progress | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 20-Apr-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 12-Jan-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 07-Jul-2020 | $50M | $50M | Completed | Generating Revenue | |
| 1. University Spin-Out | 01-Jan-2018 | Completed | Startup |
Tessera Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 3,298,161 | $0.001000 | $2 | $2 | 1x | $2 | 3.97% | |
| Series A | 14,809,929 | $0.001000 | $1 | $1 | 1x | $1 | 17.82% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Tessera Therapeutics Comparisons
Industry
Financing
Details
Tessera Therapeutics Competitors (17)
One of Tessera Therapeutics’s 17 competitors is Arbor Biotechnologies, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arbor Biotechnologies | Venture Capital-Backed | Cambridge, MA | ||||
| Mammoth Biosciences | Venture Capital-Backed | Brisbane, CA | ||||
| Recombinetics | Venture Capital-Backed | Eagan, MN | ||||
| Egenesis | Venture Capital-Backed | Cambridge, MA | ||||
| Healx | Venture Capital-Backed | Cambridge, United Kingdom |
Tessera Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tessera Therapeutics Patents
Tessera Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250092375-A1 | Cas endonucleases and related methods | Pending | 26-Jul-2023 | ||
| US-20250092426-A1 | Cas endonucleases and related methods | Pending | 26-Jul-2023 | ||
| US-20240252682-A1 | Hbb-modulating compositions and methods | Pending | 08-Sep-2021 | ||
| US-20240263153-A1 | Integrase compositions and methods | Pending | 26-May-2021 | ||
| US-20240042058-A1 | Tissue-specific methods and compositions for modulating a genome | Pending | 26-Feb-2021 | A61K48/0058 |
Tessera Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tessera Therapeutics Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abu Dhabi Investment Authority | Sovereign Wealth Fund | Minority | ||
| ARTIS Ventures | Venture Capital | Minority | ||
| Catalio Capital Management | Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| EDBI | Corporate Venture Capital | Minority |
Tessera Therapeutics FAQs
-
When was Tessera Therapeutics founded?
Tessera Therapeutics was founded in 2018.
-
Where is Tessera Therapeutics headquartered?
Tessera Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Tessera Therapeutics?
Tessera Therapeutics has 348 total employees.
-
What industry is Tessera Therapeutics in?
Tessera Therapeutics’s primary industry is Biotechnology.
-
Is Tessera Therapeutics a private or public company?
Tessera Therapeutics is a Private company.
-
What is Tessera Therapeutics’s current revenue?
The current revenue for Tessera Therapeutics is .
-
How much funding has Tessera Therapeutics raised over time?
Tessera Therapeutics has raised $580M.
-
Who are Tessera Therapeutics’s investors?
Abu Dhabi Investment Authority, ARTIS Ventures, Catalio Capital Management, Cormorant Asset Management, and EDBI are 5 of 24 investors who have invested in Tessera Therapeutics.
-
Who are Tessera Therapeutics’s competitors?
Arbor Biotechnologies, Mammoth Biosciences, Recombinetics, Egenesis, and Healx are some of the 17 competitors of Tessera Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
